By Kevin McCauley
Sard Verbinnen & Co. is guiding Britain’s largest pharmaceutical company GlaxoSmithKline as it notches a deal to acquire Human Genome Sciences of Rockville, MD, with a sweetened $3.6B acquisition bid.
HGS, which is repped by Joele Frank, Wilkinson Brimmer Katcher, rejected as too low a $2.6B offer from GSK in April.
Reuters calls HGS “an early pioneer of gene-based drug discovery” that will help GSK as its older medicines come off patents.
Andrew Witty, CEO of GSK, said in a statement that he’s “pleased to have reached a mutually beneficial agreement with HGS n friendly terms.”
He views the deal as a “natural next step in our nearly 20-year relationship with HGS.
SV&C chairman/CEO George Sard, managing director Andrew Cole and principal Michael Henson are staffers working on behalf of GSK.
They match up against managing partner Joele Frank, and partners Dan Katcher and Jamie Moser repping HGS. |